Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization

Modern Pathology

Volumn 10, Issue 7, 1997, Pages 720-727

  Persons, D L ^a,c   Borelli, K A ^a   Hsu, P H ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b ABBOTT LABORATORIES   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Breast cancer; c myc; FISH; HER 2 neu

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MYC PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; DIAGNOSTIC VALUE; DNA DETERMINATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE DIAGNOSIS; REPRODUCIBILITY;

BREAST NEOPLASMS; EVALUATION STUDIES; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; GENES, MYC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS;

EID: 0030763180     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
2. Varley JM, Swallow JE, Brammer WJ, Whittaker JL, Walker RA. Alterations to either c-erb-B2 (neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1987;1:423-30.
3. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
4. Paterson MC, Dietrich KD, Paterson AHG, Lees AW, Jamil N, Hanson J, et al. Correlation between c-erb-B-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 1991;51:556-67.
5. Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, et al. c-erb-B-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991;63:434-8.
6. Berns EMJJ, Foekens JA, van Putten WLJ, van Staveren IL, Portengen H, de Koning WCH, et al. Prognostic factors in human primary breast cancer: comparison of c-myc and HER-2/neu amplification. J Steroid Biochem Mol Biol 1992; 43:13-9.
7. Gasparini G, Gullick WJ, Bevilacqua P, Sainsbury JRC, Meli S, Boracchi P, et al. Human breast cancer: prognostic significance of the c-erb-B-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 1992;10:686-95.
8. Allred DC, Clark DGM, Tandon AK, Molina R, Tormey DC, Osborne CK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992;10:599-605.
9. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, et al. HER-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-70.
10. Lonn U, Lonn S, Nilsson B, Stenkvist B. Prognostic value of erb-B2 and myc amplification in breast cancer imprints. Cancer 1995;75:2681-7.
11. Berns EMJJ, Klijn JGM, van Putten WLJ, van Staveren IL, Portengen H, Foekens JA. c-myc amplification is a better prognostic factor than HER-2/neu amplification in primary breast cancer. Cancer Res 1992;52:1107-13.
12. Roux-Dossetto M, Romain S, Dussault N, Desideri C, Piana L, Bonnier P, et al. c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse. Eur J Cancer 1992;28A:1600-4.
13. Borg A, Baldetorp B, Ferno M, Olsson H, Sigurdsson H. c-myc amplification is an independent prognostic factor in post-menopausal breast cancer. Int J Cancer 1992;51:687-91.
14. Pertschuk LP, Feldman JG, Kim DS, Nayeri K, Eisenberg KB, Carter AC, et al. Steroid hormone receptor immunohistochemistry and amplification of the c-myc proto-oncogene. Cancer 1993;71:161-71.
15. Watson PH, Safneck JR, Le K, Dubik D, Shiu RPC. Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis. J Natl Cancer Inst 1993;85:902-7.
16. Berns EMJJ, Klijn JGM, Smid M, van Staveren IL, Look MP, van Putten WLJ, et al. TP53 and myc gene alterations independently predict poor prognosis in breast cancer patients. Genes Chromosom Cancer 1996;16:170-9.
17. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-12.
18. Babiak J, Hugh J, Poppema S. Significance of c-erb-B-2 amplification and DNA aneuploidy: analysis of 78 patients with node-negative breast cancer. Cancer 1992;70:770-6.
19. Kinouchi T, Saiki S, Naoe T, Uenaka A, Kotake T, Shiku H, et al. Correlation of c-myc expression with nuclear pleomorphism in human renal cell carcinoma. Cancer Res 1989;49: 3627-30.
20. Melhem MF, Meisler AI, Finley GG, Bryce WH, Jones MO, Tribby II, et al. Distribution of cells expressing myc proteins in human colorectal epithelium, polyps, and malignant tumors. Cancer Res 1992;52:5853-64.
21. Evan GI, Littlewood TD. The role of c-myc in cell growth. Curr Opin Genet Dev 1993;3:44-9.
22. Koskinen PJ, Alitalo K. Role of myc amplification and over-expression in cell growth, differentiation, and death. Semin Cancer Biol 1993;4:3-12.
23. Alarcon RM, Rupnow BA, Graeber TG, Knox SJ, Giaccia AJ. Modulation of c-myc activity and apoptosis in vivo. Cancer Res 1996;56:4315-9.
24. Pietilainen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma V-M, Syrjanen K. Expression of c-myc proteins in breast cancer as related to established prognostic factors and survival. Anticancer Res 1995;15:959-64.
25. Persons DL, Hartmann LC, Herath JF, Borell TJ, Cliby WA, Keeney GL, et al. Interphase cytogenetic analysis of epithelial ovarian carcinomas. Am J Pathol 1993;142:733-41.
26. Persons DL, Robinson RA, Hsu PH, Seelig SA, Borell TJ, Hartmann LC, et al. Chromosome-specific aneusomy in carcinoma of the breast. Clin Cancer Res 1996;2:883-8.
27. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991;51: 944-8.
28. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al. c-erb-B-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-6.
29. Bitran JD, Samuels B, Trujillo Y, Klein L, Schroeder L, Martinec J. HER-2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (more than 10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. Clin Cancer Res 1996;2:1509-13.
30. Kallioniemi O, Kallioniemi A, Kurisu W, Thor A, Chen L-C, Smith HS, et al. erb-B-2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A 1992;89:5321-5.
31. Lee AKC, Wiley B, Loda M, Bosari, S, Dugan JM, Hamilton W, et al. DNA ploidy, proliferation, and neu-oncogene protein overexpression in breast carcinoma. Mod Pathol 1992;5:61-7.
32. Ciocca DR, Fujimura FK, Tandon AK, Clark GM, Mark C, Lee-Chen G-J, et al. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst 1992;84:1279-82.
33. Henry JA, Hennessy C, Levett DL, Lennard TWJ, Westly BR, May FEB. int-2 amplification in breast cancer: association with decreased survival and relationship to amplification of c-erb-B-2 and c-myc. Int J Cancer 1993;53:774-80.
34. Keshgegian AA. erb-B-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically and immunohistochemically determined hormone receptors. Breast Cancer Res Treat 1995;35:201-20.
35. Adnane J, Gaudray P, Simon M-P, Simony-Lafontaine J, Jeanteur P, Theillet C. Proto-oncogene amplification and human breast tumor phenotype. Oncogene 1989;4:1389-95.
36. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-7.
37. Greer CE, Pertson SL, Kiviat NB, Manos MM. PCR amplification from paraffin-embedded tissue. Effects of fixation and fixation time. Am J Clin Pathol 1991;95:117-24.
38. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63-72.